Phaseline

Targets › GNAQ

GNAQ (Guanine nucleotide-binding protein G(q) subunit alpha): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Oct 2027.

Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signaling cascades. The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state. (UniProt, P50148)

Open in Phaseline: the race on GNAQ, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisDYP688
GNAQ/GNA11 inhibitor
GNAQ, GNA11Phase 1Metastatic Uveal MelanomaOct 2027

Conditions

Metastatic Uveal Melanoma (1)

Modalities

small molecule (1)

Companies

Novartis (1)

Related targets

GNA11 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.